Related Experiment Video

Updated: Jul 5, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Apoptotic pathways in tumor progression and therapy

Armelle Melet1, Keli Song, Octavian Bucur

  • 1Department of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, 99 Brookline Avenue, Boston, MA 02215, USA.

Advances in Experimental Medicine and Biology
|April 29, 2008
PubMed

Insights

Cancer cells evade apoptosis, a programmed cell death process, leading to uncontrolled growth and chemotherapy resistance. New targeted therapies aim to restore apoptosis for effective cancer treatment.

Area of Science:

  • Cell biology
  • Cancer research
  • Pharmacology

Background:

  • Apoptosis, or programmed cell death, is crucial for development and tissue balance.
  • Cancer cells evade apoptosis, contributing to uncontrolled proliferation and therapeutic resistance.
  • Dysregulation of apoptosis pathways is a hallmark of cancer progression and treatment failure.

Purpose of the Study:

  • To review current understanding of apoptosis regulation in cancer.
  • To explore the role of apoptosis in cancer progression and therapeutic response.
  • To highlight novel molecular targets for pro-apoptotic cancer therapies.

Main Methods:

  • Literature review of apoptosis signaling pathways.
  • Analysis of dysregulation in cancer progression.
  • Examination of targeted pro-apoptotic therapies in drug development.

Main Results:

  • Significant progress in understanding apoptosis regulation in cancer.
  • Identification of apoptosis evasion as a key cancer trait.
  • Emergence of molecularly targeted pro-apoptotic therapies.

Conclusions:

  • Restoring apoptosis is a promising strategy for cancer therapy.
  • Targeted molecules are being developed to induce cancer cell death.
  • New pro-apoptotic therapies show potential in preclinical and clinical settings.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Apoptosis01:30

Apoptosis

Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...